Skip to content
10-K

Annual Report

BRIACELL THERAPEUTICS CORP. BCTX BCTXL BCTXZ

0001493152-25-018212

← back to feed
Filed
Oct 16, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Oct 15, 2025 1.88M sh
Shares Diluted FY 2025 · Jul 31, 2025 423.11K sh
Shares Diluted restated FY 2025 · Jul 31, 2024 109.7K sh
Operating Cash Flow FY 2025 · Jul 31, 2025 −$28.17M
Operating Cash Flow FY 2025 · Jul 31, 2024 −$24.13M
Short Term Investments FY 2025 · Jul 31, 2025 $7.37M
Cash And Equivalents FY 2025 · Jul 31, 2025 $10.49M
Cash And Equivalents FY 2025 · Jul 31, 2024 $862.09K
Current Liabilities FY 2025 · Jul 31, 2025 $3.98M
Current Liabilities FY 2025 · Jul 31, 2024 $7.46M
Current Assets FY 2025 · Jul 31, 2025 $19.93M
Current Assets FY 2025 · Jul 31, 2024 $3.65M
Total Assets FY 2025 · Jul 31, 2025 $21.65M
Total Assets FY 2025 · Jul 31, 2024 $5.87M
Eps Diluted FY 2025 · Jul 31, 2025 −$62.19
Eps Diluted restated FY 2025 · Jul 31, 2024 −$43.68
Eps Basic FY 2025 · Jul 31, 2025 −$62.19
Eps Basic restated FY 2025 · Jul 31, 2024 −$43.68
Sga Expense FY 2025 · Jul 31, 2025 $5.93M
Sga Expense FY 2025 · Jul 31, 2024 $6.15M
Rd Expense FY 2025 · Jul 31, 2025 $21.27M
Rd Expense FY 2025 · Jul 31, 2024 $27.18M
Net Income FY 2025 · Jul 31, 2025 −$26.31M
Net Income FY 2025 · Jul 31, 2024 −$4.79M
Operating Income FY 2025 · Jul 31, 2025 −$27.2M
Operating Income FY 2025 · Jul 31, 2024 −$33.33M
Capex FY 2025 · Jul 31, 2024 $456.8K